Evidence map›Paper›PMID 37621850›Full record

ArticleFuture science OA2023

Hen egg white bovine colostrum supplement reduces symptoms of mild/moderate COVID-19: a randomized control trial.

Jaclyn Kelly Mann, Tarylee Reddy, Mary van der Stok, Ayanda Ngubane, Takalani Mulaudzi, Nobuhle Mchunu, Portia Nevhungoni, Nithendra Manickchund, Pariva Manickchund, Chelline Helena Louise Cairns and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Jaclyn Kelly MannHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, 4001, South Africa.ORCID https://orcid.org/0000-0002-2398-1273
Tarylee ReddyBiostatistics Research Unit, South African Medical Research Council, Durban, 4091, South Africa.
Mary van der StokHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, 4001, South Africa.
Ayanda NgubaneHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, 4001, South Africa.
Takalani MulaudziHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, 4001, South Africa.
Nobuhle MchunuBiostatistics Research Unit, South African Medical Research Council, Durban, 4091, South Africa.
Portia NevhungoniBiostatistics Research Unit, South African Medical Research Council, Durban, 4091, South Africa.
Nithendra ManickchundDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, 4001, South Africa.
Pariva ManickchundDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, 4001, South Africa.
Chelline Helena Louise CairnsDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, 4001, South Africa.
Vaneshree GovenderAurum Institute, Johannesburg, 2194, South Africa.
Thumbi Ndung'uHIV Pathogenesis Programme, University of KwaZulu-Natal, Durban, 4001, South Africa.
Mahomed Yunus Suleman MoosaDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, 4001, South Africa.
Bernadett Isabel GosnellDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, 4001, South Africa.
University of KwaZulu-Natal · ZASouth African Medical Research Council · ZAAurum Institute · ZARagon Institute of MGH, MIT and Harvard · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The ability of a hen egg white bovine colostrum supplement to prevent severe COVID-19 was tested in a double-blind randomized control study. Methods: Adults with mild/moderate COVID-19, risk factors for severe disease, and within 5 days of symptom onset were assigned to the intervention (n = 77) or placebo (n = 79) arms. Symptoms were documented until day 42 post-enrollment and viral clearance was assessed at 11-13 days post-symptom onset. Results: One participant developed severe COVID-19. The severe-type symptom score was lower in the active arm at 11-13 days post-symptom onset (p = 0.049). Chest pain, fever/chills, joint pain/malaise, and sore throat were significantly less frequent in the active arm. No differences in viral clearance were observed. Conclusion: The intervention reduced symptoms of mild/moderate COVID-19. Clinical Trial Registration: DOH-27-062021-9191 (South African National Clinical Trials Register).

Indexed as

colostrumcoronavirusCOVID-19deltaegg whitelactoferrinlysozymenutritional supplementomicronovotransferrin

Identifiers

PMID37621850
PMCPMC10445555
OpenAlexW4384931648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.